Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Shares Outstanding (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Shares Outstanding for 10 consecutive years, with $67.2 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 7.72% to $67.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $67.2 million through Dec 2025, up 7.72% year-over-year, with the annual reading at $67.2 million for FY2025, 7.72% up from the prior year.
  • Shares Outstanding for Q4 2025 was $67.2 million at Rhythm Pharmaceuticals, up from $66.7 million in the prior quarter.
  • The five-year high for Shares Outstanding was $67.2 million in Q4 2025, with the low at $50.2 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $57.7 million, with a median of $58.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding increased 13.87% in 2021, then increased 0.38% in 2022.
  • Over 5 years, Shares Outstanding stood at $50.3 million in 2021, then grew by 12.59% to $56.6 million in 2022, then increased by 4.97% to $59.4 million in 2023, then grew by 4.99% to $62.4 million in 2024, then grew by 7.72% to $67.2 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $67.2 million, $66.7 million, and $63.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.